MedTrace Logo

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT00640523 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2012-01-23

No results posted yet for this study

Summary

To evaluate the effectiveness and safety of forodesine in CLL patients

Conditions

  • Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

forodesine HCl

2 x 100mg capsules daily

Sponsors & Collaborators

  • BioCryst Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Asher Chanan-Khan, MD · Roswell Park Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-11-30
Completion
2011-11-30

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00640523 on ClinicalTrials.gov